- Home
- AGL vs VRDN Comparison
AGL vs VRDN Comparison
Compare AGL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | VRDN |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AGL | VRDN |
|---|---|---|
| Price | $106.03 | $15.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $55.68 | $35.46 |
| AVG Volume (30 Days) | 296.0K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $5,932,576,000.00 | $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | $4.23 | $279.00 |
| P/E Ratio | $34.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $13.18 |
| 52 Week High | $104.55 | $34.29 |
Technical Indicators
Market Signals| Indicator | AGL | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 76.31 | 42.32 |
| Support Level | $0.62 | $13.26 |
| Resistance Level | N/A | $18.05 |
| Average True Range (ATR) | 8.27 | 0.81 |
| MACD | -0.50 | -0.10 |
| Stochastic Oscillator | 88.05 | 0.74 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.